Many state Medicaid programs have been fighting the opioid epidemic by purchasing and distributing the lifesaving opioid-reversal drug naloxone. Harvard’s Richard G. Frank and Carrie E. Fry report on evidence showing that states that have actively promoted naloxone experienced 9 percent to 11 percent reductions in opioid-related deaths. The authors say the proposed cuts to state Medicaid funding in both the House and Senate health care bills could jeopardize financial access to this lifesaving drug.
Medicaid Expands Access to Lifesaving Naloxone
